deltatrials
Terminated OBSERVATIONAL NCT02928510

Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic Lymphoma

Idelalisib (GS-1101)-Associated Colitis - Molecular and Cellular Mechanisms Research Proposal

Sponsor: Gilead Sciences

Conditions Absence of Signs or Symptoms B-Cell Non-Hodgkin Lymphoma Digestive System Signs and Symptoms Indolent Adult Non-Hodgkin Lymphoma Recurrent B-Cell Non-Hodgkin Lymphoma Recurrent Chronic Lymphocytic Leukemia Recurrent Indolent Adult Non-Hodgkin Lymphoma Recurrent Small Lymphocytic Lymphoma
Interventions Biospecimen Collection Colonoscopy Colposcopic Biopsy Idelalisib Laboratory Biomarker Analysis Pharmacological Study Physical Examination Sigmoidoscopy
Updated 12 times since 2017 Last updated: Jul 12, 2021 Started: Feb 1, 2016 Primary completion: Jun 5, 2018 Completion: Jun 5, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

withdrawn by sponsor

Other terminated trials from Gilead Sciences

See all terminations from Gilead Sciences

This observational or N/A phase trial investigates Absence of Signs or Symptoms and B-Cell Non-Hodgkin Lymphoma and is currently terminated or withdrawn. Gilead Sciences leads this study, which shows 12 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Oct 2017 · 9 months · monthly snapshotNot Yet Recruiting~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshotRecruiting~Jun 2018 – ~Mar 2019 · 9 months · monthly snapshotRecruiting~Mar 2019 – ~Jul 2020 · 16 months · monthly snapshotTerminated~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshotTerminated~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshotTerminated~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshotTerminated~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshotTerminated~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshotTerminated~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

12 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated

  3. Dec 2021 — Jul 2024 [monthly]

    Terminated

  4. Sep 2021 — Dec 2021 [monthly]

    Terminated

    Phase: NA → None

  5. Jun 2021 — Sep 2021 [monthly]

    Terminated NA

▶ Show 7 earlier versions

  1. Jan 2021 — Jun 2021 [monthly]

    Terminated NA

  2. Aug 2020 — Jan 2021 [monthly]

    Terminated NA

  3. Jul 2020 — Aug 2020 [monthly]

    Terminated NA

  4. Mar 2019 — Jul 2020 [monthly]

    Terminated NA

    Status: Recruiting → Terminated

  5. Jun 2018 — Mar 2019 [monthly]

    Recruiting NA

  6. Oct 2017 — Jun 2018 [monthly]

    Recruiting NA

    Status: Not Yet Recruiting → Recruiting

  7. Jan 2017 — Oct 2017 [monthly]

    Not Yet Recruiting NA

    First recorded

Feb 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Gilead Sciences
  • Jonsson Comprehensive Cancer Center
Data source: Jonsson Comprehensive Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations